Van Dieren J M, Hansen B E, Kuipers E J, Nieuwenhuis E E S, Van der Woude C J
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Aliment Pharmacol Ther. 2007 Sep 1;26(5):643-52. doi: 10.1111/j.1365-2036.2007.03412.x.
Thiopurines are widely used for the treatment of inflammatory bowel disease, but are associated with the development of side effects. It has been suggested that the enzyme inosine triphosphate pyrophosphatase (ITPA) plays a role in the digestion of thiopurines and that defective activity resulting from polymorphisms in the inosine triphosphate pyrophosphatase encoding genes may be associated with thiopurine-induced side effects. Current studies are controversial regarding this hypothesis.
To perform a meta-analysis and gain more insight into a possible correlation between thiopurine-induced side effects and ITPA polymorphisms.
We explored Medline for articles on ITPA polymorphisms and thiopurine toxicity. Studies that compared ITPA polymorphism frequencies among thiopurine-tolerant and -intolerant adult inflammatory bowel disease patients were included in this meta-analysis.
Nine published studies investigated associations between ITPA polymorphisms and thiopurine toxicity. Six studies (with 751 patients included) met our inclusion criteria and were processed in the meta-analysis. This analysis demonstrates that the ITPA 94C-->A polymorphism, is not significantly associated with any of the studied side effect parameters.
This meta-analysis does not prove a correlation between the development of thiopurine toxicity and the ITPA 94C-->A polymorphism. This implies that there is no clinical relevance to determine ITPA polymorphisms in thiopurine-treated patients.
硫唑嘌呤广泛用于治疗炎症性肠病,但会引发副作用。有人提出肌苷三磷酸焦磷酸酶(ITPA)在硫唑嘌呤的代谢中起作用,并且肌苷三磷酸焦磷酸酶编码基因多态性导致的活性缺陷可能与硫唑嘌呤引起的副作用有关。目前关于这一假说的研究存在争议。
进行一项荟萃分析,以更深入了解硫唑嘌呤引起的副作用与ITPA多态性之间可能存在的相关性。
我们在Medline上搜索关于ITPA多态性和硫唑嘌呤毒性的文章。本荟萃分析纳入了比较硫唑嘌呤耐受和不耐受的成年炎症性肠病患者中ITPA多态性频率的研究。
九项已发表的研究调查了ITPA多态性与硫唑嘌呤毒性之间的关联。六项研究(纳入751例患者)符合我们的纳入标准,并进行了荟萃分析。该分析表明,ITPA 94C→A多态性与任何研究的副作用参数均无显著相关性。
这项荟萃分析并未证明硫唑嘌呤毒性的发生与ITPA 94C→A多态性之间存在相关性。这意味着在硫唑嘌呤治疗的患者中检测ITPA多态性没有临床意义。